recombinant fusion protein nhba of neisseria meningitidis group b
SpainDrugs containing this active substance
-
It is a vaccine that helps protect against serious diseases caused by the Neisseria meningitidis group B bacteria, such as meningitis and sepsis.
Form: suspension for injection
Active substance Dosage recombinant fusion protein nhba of neisseria meningitidis group b 50 µg recombinant protein nada of neisseria meningitidis group b 50 µg recombinant fhbp fusion protein from neisseria meningitidis group b 50 µg outer membrane vesicles (omv) of neisseria meningitidis group b (strain nz98/254 measured as the total protein content of the pora p1.4) 25 µg Manufacturer: Glaxosmithkline Vaccines S.R.L.